

Certificate of Analysis - Amended Distribution Lot

Product Description	WA09 (H9) Distribution Lot
Cell Line Provider	WiCell
MCB Lot Number	(WA09) H9-MCB-1
Distribution Lot Number	WA09 (H9)-DL-5
Date Vialed	1-April-2008
Passage Number	p25
Culture Method	SOP-CC-030B, SOP-CC-001B, SOP-CC-022B, SOP- CC-020B, SOP-CC-037A
Cryopreservation Method	SOP-CC-035D

The following testing specifications have been met for the specified product lot:

Test Description	Test Method	Test Specification	Result
Post-Thaw Viable Cell Recovery	SOP-CH-305A	Viable cells recovered	Pass
Identity by STR	SOP-CH-302A	Positive identity	Pass
Sterility - Direct transfer method	SOP-CH-304A	No contamination detected	Pass
Mycoplasma	SOP-CH-320A	No contamination detected	Pass
Karyotype by G-banding	SOP-CH-003A	Normal karyotype	Pass

Comparative Genome Hybridization	SOP-SS-010A SOP-CH-309A SOP-CH-310A SOP-SS-001A	Report copy number variants	Report available on website
Flow Cytometry for ESC Marker Expression	SOP-CH-101B SOP-CH-102B SOP-CH-103B SOP-CH-105B	Report values Oct-4 > 90%	Report available on website
Gene Expression Profile	SOP-CH-321A SOP-CH-322A SOP-CH-333A SOP-CH-311B	Report level of gene expression	Report available on website

Distribution lot cells are expanded from vials of Master Cell Bank (MCB) cells. MCB cells are thoroughly tested and known to be free of many viruses and pathogens. Cells distributed by the National Stem Cell Bank are intended for research purposes only and are not intended for use in humans. These cells have undergone extensive testing and are not known to harbor any human pathogens or adventitious agents of murine, bovine, or

©2008 WiCell Research Institute The material provided under this certificate has been subjected to the tests specified and the results and data described herein are accurate based on WiCell's reasonable knowledge and belief. Appropriate Biosafety Level practices and universal precautions should always be used with this material. For clarity, the foregoing is governed solely by WiCell's Terms and Conditions of Service, which can be found at http://www.wicell.org/privacyandterms.



Certificate of Analysis - Amended Distribution Lot

porcine origin. However, appropriate biosafety precautions should be followed when working with these cells. The end user is responsible for ensuring that the cells are handled and stored in an appropriate manner. The NSCB is not responsible for damages or injuries that may result from the use of these cells.

Electronic versions of the MCB and distribution lot certificates (CoAs) complete with electronic copies of individual reports, results, and procedures are available on our website, www.wicell.org. There are also archived CoAs for past cell lots.

Please visit the technical service portion of the website for assistance with your human ES Cells. The knowledgeable technical support staff can assist with embryonic stem cell culture concerns, training, and any other customer service concerns you may encounter.

Amendment(s):

Reason for Amendment	
CoA updated to include copyright information and electronic signature, and update to WiCell logo. Links updated.	
CoA updated to include copyright information and electronic signature, and update to WiCell logo. Links updated. Original CoA	

Date of Lot Release	Quality Assurance Approval		
15-September-2008	1/3/2014 X AMC AMC Quality Assurance Sganed by:		



University of Wisconsin Hospital and Clinics

Short Tandem Repeat Analysis*

Sample Report: 1297-STR WA09-DL-7

UW HLA#: 59442

Sample Date: 09/04/08 Received Date: 09/04/08

Requestor: WiCell Research Institute

Test Date: 09/10/08, 09/17/08

File Name: 080911, 080918 Report Date: 09/19/08

Sample Name: (label on tube) 1297-STR

Description: DNA Extracted by WiCell 229 ug/mL; 260/280 = 1.9

Locus	Repeat #	STR Genotype
D16S539	5, 8-15	12,13
D7S820	6-14	9,11
D13S317	7-15	9,9
D5S818	7-15	11,12
CSF1PO	6-15	11,11
TPOX	6-13	10,11
Amelogenin	NA	X,X
TH01	5-11	9.3,9.3
vWA	11, 13-21	17,17


Comments: Based on the DNA 1297-STR dated and received on 09/04/08 from WI Cell, this sample (UW HLA# 59442) matches exactly the STR profile of the human stem cell line H9 comprising 12 allelic polymorphisms across the 8 STR loci analyzed. No STR polymorphisms other than those corresponding to the human H9 stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the 1297-STR DNA sample submitted corresponds to the H9 stem cell line and it was not contaminated with any other human stem cells or a significant amount of mouse feeder layer cells. Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~5%. A preliminary copy of this report was issued via electronic mail to the WI Cell Research Institute on Monday, September 22, 2008.

^{*} Testing to assess engraftment following bone marrow transplantation was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only.

Test Facility: 1265 Kennestone Circle Marietta, GA 30066

This report is confidential. No part may be used for advertising or public announcement without written permission. Results apply only to the sample(s) tested.

WuXi AppTec



Sample Information: hES Cells 1: WA09-DL-6 2: WA09-DL-7 Date Received: July 23, 2008 Date in Test: July 25, 2008 **Date Completed:** August 08, 2008 **Test Information:** Test Codes: 30744, 30744A Immersion, USP / 21 CFR 610.12 Procedure #: BS210WCR.201

QA Reviewed: Amy J. B. 08-12-02

Reviewed: Erika Hailes 08-11-08

Testing conducted in accordance with current Good Manufacturing Practices.

Test Facility: 1265 Kennestone Circle Marietta, GA 30066 This report is confidential. No part may be used for advertising or public announcement without written permission. Results apply only to the sample(s) tested.

WuXi AppTec

Report Number 783245 Page 3 of 3

WiCell Research Institute

August 11, 2008 P.O. #: RP2030

STERILITY TEST REPORT

Sample Information:	hES Cells		
	2: WA09-DL-7		
Date Received:	July 23, 2008		
Date in Test:	July 25, 2008		
Date Completed:	August 08, 2008		

Test Information: Test Codes: 30744, 30744A Immersion, USP / 21 CFR 610.12 Procedure #: BS210WCR.201

TEST PARAMETERS	PRODUCT		
Approximate Volume Tested	0.5 mL	0.5 mL	
Number Tested	2	2	
Type of Media	SCD	FTM	
Media Volume	400 mL	400 mL	
Incubation Period	14 Days	14 Days	
Incubation Temperature	20 °C to 25 °C	30 °C to 35 °C	
RESULTS	2 NEGATIVE	2 NEGATIVE	

QA Reviewed:

Page 1 Signed

Reviewed:

Page 1 Signed

Testing conducted in accordance with current Good Manufacturing Practices.

1265 Kennestone Circle • Marietta, GA 30066 • 888.847.6633 • 770.514.0262 • Fax 770.514.0294



FINAL STUDY REPORT

STUDY TITLE:

MYCOPLASMA DETECTION: "Points to Consider"

PROTOCOL NUMBER:

30055F

TEST ARTICLE IDENTIFICATION:

WA09-DL-5

SPONSOR:

WiCell Research Institute

PERFORMING LABORATORY:

WuXi AppTec, Inc. 2540 Executive Drive St. Paul, MN 55120

STUDY NUMBER:

108515

RESULT SUMMARY:

Considered **negative** for mycoplasma contamination

Reference PO # RP1983



QUALITY ASSURANCE UNIT SUMMARY

STUDY: Mycoplasma Detection: "Points to Consider"

The objective of the Quality Assurance Unit is to monitor the conduct and reporting of nonclinical laboratory studies. This study has been performed under Good Laboratory Practices regulations (FDA, 21 CFR. Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies) and in accordance to standard operating procedures and a standard protocol. The Quality Assurance Unit maintains copies of study protocols and standard operating procedures and has inspected this study on the dates listed below. Studies are inspected at time intervals to assure the quality and integrity of the study.

Critical Phase Staining of coverslips Final Report

Date 07/11/08 08/13/08 Study Director 07/15/08 08/13/08

Management 08/14/08 08/14/08

The findings of these inspections have been reported to management and the Study Director.

Quality Assurance Auditor:

ALCON SCOTT W. Sherma

9-14-08 Date:

GOOD LABORATORY PRACTICES STATEMENT

The study referenced in this report was conducted in compliance with U.S. Food and Drug Administration Good Laboratory Practice (GLP) regulations set forth in 21 CFR part 58.

The studies not performed by or under the direction of WuXi AppTec, Inc., are exempt from this Good Laboratory Practice Statement and include characterization and stability of the test compound(s)/test article.

Study Director: their & zielinski Date: 8/14/08

Professional Personnel Involved:

Lisa Olson, BS Sheri Zielinski, BS Jean Mesarich, AA

Vice President of St. Paul Operations Study Director **Client Relations Manager**




Copy of Original

1.0 PURPOSE

To demonstrate that a test article consisting of a cell bank, production or seed lots, or raw materials is free of mycoplasmal contamination, according to "Points to Consider" criteria.

2.0 SPONSOR:





3.0 TEST FACILITY: WuXi AppTec, Inc. 2540 Executive Drive St. Paul, MN 55120

4.0 SCHEDULING

DATE SAMPLE RECEIVED:	07/01/08
STUDY INITIATION DATE:	07/03/08
STUDY COMPLETION DATE:	08/14/08

5.0 TEST ARTICLE IDENTIFICATION: WiCell Research Institute WA09-DL-5

6.0 SAMPLE STORAGE

Upon receipt by the Sample Receiving Department, the test samples were placed in a designated, controlled access storage area ensuring proper temperature conditions. Test and control article storage areas are designed to preclude the possibility of mix-ups, contamination, deterioration or damage. The samples remained in the storage area until retrieved by the technician for sample preparation and/or testing. Unused test samples remained in the storage area until the study was completed. Once completed, the remaining samples were discarded or returned as requested by the Sponsor.

7.0 TEST ARTICLE CHARACTERIZATION

The Sponsor was responsible for all test article characterization data as specified in the GLP regulations. The identity, strength, stability, purity, and chemical composition of the test article were solely the responsibility of the Sponsor. The Sponsor was responsible for supplying to the testing laboratory results of these determinations and any others that may have directly impacted the testing performed by the testing laboratory, prior to initiation of testing. Furthermore, it was the responsibility of the Sponsor to ensure that the test article submitted for testing was representative of the final product that was subjected to materials characterization. Any special requirements for handling or storage were arranged in advance of receipt and the test article was received in good condition.

The Vero cells were maintained by WuXi AppTec's Cell Production Laboratory.

8.0 EXPERIMENTAL DESIGN

8.1 Overview

Whereas no single test is capable of detecting all mycoplasmal strains, freedom from mycoplasmal contamination may be demonstrated by the use of both an indirect and direct procedure.



Copy of Original

8.2 Justification for Selection of the Test System

Contamination of cell cultures by mycoplasma is a common occurrence and is capable of altering normal cell structure and function. Among other things, mycoplasma may affect cell antigenicity, interfere with virus replication, and mimic viral actions. Testing for the presence of mycoplasma for cell lines used to produce biologicals is recommended by the FDA, Center for Biologics Evaluation and Research (CBER) under "Points to Consider."

9.0 EXPERIMENTAL SUMMARY

The indirect method of detection allows visualization of mycoplasma, particularly noncultivable strains, by growing the mycoplasma on an indicator cell line and then staining using a DNA-binding fluorochrome stain. The indicator cell line should be easy to grow, have a large cytoplasmic to nuclear area ratio and support the growth of a broad spectrum of mycoplasma species. The African green monkey kidney cell line, Vero, fits this description and was used in this assay. The assay was performed with negative and positive controls. Both a strongly cyto-adsorbing (*M. hyorhinis*) and a poorly cyto-adsorbing (*M. orale*) mycoplasma species were used as positive controls. Poor cyto-adsorbing mycoplasma species may not give reliable positive results when inoculated in low numbers. A second dilution of *M. orale* was used to ensure cyto-adsorption. Staining the cultures with DNA binding fluorochrome allows for the detection of mycoplasma based on the staining pattern observed. Only the cell nuclei demonstrate fluorescence in the negative cultures but nuclear and extra-nuclear fluorescence is observed in positive cultures.

Direct cultivation is a sensitive and specific method for the detection of mycoplasma. The agar and broth media employed supply nutrients necessary for the growth of cultivable mycoplasmas. These media also supply a source of carbon and energy, and favorable growth conditions. The direct assay was performed with both negative and positive controls. A fermentative mycoplasma (*M. pneumoniae*) and a non-fermentative mycoplasma (*M. orale*) were used as positive controls. The procedure employed in this study is based on the protocol described in the 1993 Attachment # 2 to the "Points To Consider" document, as recommended by the FDA, Center for Biologics Evaluation and Research (CBER).

10.0 TEST MATERIAL PREPARATION

10.1 Test Article Identification:

Test Article Name: Lot/Batch #: General Description: Number of Aliquots used: Stability (Expiration): Storage Conditions: Safety Precautions:	WA09-DL-5 Not Given hES cells 1 x 15 mL Not Given Ultracold (< -60°C) BSL-1
Intended Use/Application:	Not Given



10.2 Test Sample Preparation

The test article was thawed in a water bath at $37 \pm 2^{\circ}$ C and 1:5 and 1:10 dilutions of the test article were prepared in sterile phosphate buffered saline (PBS). 1.0 mL of the undiluted sample, the 1:5 and 1:10 dilutions were then inoculated onto each of two (2) coverslips (per sample/dilution) containing Vero cells. The coverslips were incubated in incubator E770 for 1-2 hours at $37 \pm 1^{\circ}$ C / $5 \pm 2^{\circ}$ CO₂ and then 2.0 mL of EMEM, 8% Fetal Bovine Serum (FBS) was added to each coverslip. The coverslips were returned to incubator E770 at $37 \pm 1^{\circ}$ C / $5 \pm 2^{\circ}$ CO₂. After three days of incubation, the coverslips were fixed, stained, and then read using an epifluorescent microscope.

0.2 mL of the undiluted test article was then inoculated onto each of two SP-4 agar plates, and 10.0 mL was inoculated into a 75 cm² flask containing 50 mL of SP-4 broth. The plates were placed in an anaerobic GasPak system and incubated at $36 \pm 1^{\circ}$ C for a minimum of 14 days.

The broth flask was incubated aerobically at $36 \pm 1^{\circ}$ C, and subcultured onto each of two SP-4 agar plates (0.2 mL/plate) on Days 3, 7, and 14. These subculture plates were placed in an anaerobic GasPak system and incubated at $36 \pm 1^{\circ}$ C for a minimum of 14 days. The broth flask was read each working day for 14 days. The SP-4 agar plates (Day 0) were read after 14 days of incubation. The SP-4 broth subculture plates (Days 3, 7, and 14) were read after 14 days incubation.

10.3 Controls and Reference Materials

10.3.1 Sterile SP-4 broth served as the negative control for both the direct and indirect assays.

10.3.2 Positive Controls

a. Indirect Assay

- **a.1** Strongly cyto-adsorbing species *M. hyorhinis* GDL (ATCC #23839) at 100 or fewer colony forming units (CFU) per inoculum.
- **a.2** Poorly cyto-adsorbing species *M. orale* (ATCC #23714) at 100 or fewer CFU and at approximately 100 ID₅₀ per inoculum

b. Direct Assay

- **b.1** Nonfermentative mycoplasma species *M. orale* (ATCC #23714) at 100 or fewer CFU per inoculum.
- **b.2** Fermentative mycoplasma species *M. pneumoniae* FH (ATCC #15531) at 100 or fewer CFU per inoculum.

10.3.3 Control Preparation

a. Negative Controls

a.1 1.0 mL of sterile SP-4 broth was inoculated onto each of two
 (2) coverslips containing Vero cells to serve as the negative control in the indirect assay.



a.2 0.2 mL of SP-4 broth was inoculated onto each of two (2) SP-4 agar plates to serve as the negative control in the direct assay. 10.0 mL of SP-4 broth was inoculated into a 75 cm² flask containing 50 mL of SP-4 broth to serve as the negative control in the direct assay.

b. Positive Controls

- b.1 *M. hyorhinis, M. orale,* and *M. pneumoniae* were diluted to less than 100 CFU per inoculum in sterile SP-4 broth. 1.0 mL of *M. hyorhinis* and *M. orale* at less than 100 CFU/mL was inoculated onto each of two (2) coverslips containing Vero cells. 1.0 mL of *M. orale* at 100 ID₅₀ CFU per inoculum was also inoculated onto each of two (2) coverslips containing Vero cells. These coverslips served as the positive controls in the indirect assay.
- **b.2** The coverslips were incubated in incubator E770 for 1-2 hours at $37 \pm 1^{\circ}$ C / $5 \pm 2\%$ CO₂ and then 2.0 mL of EMEM, 8% Fetal Bovine Serum (FBS) was added to each coverslip. The coverslips were returned to incubator E770 at $37 \pm 1^{\circ}$ C / $5 \pm 2\%$ CO₂. After three days of incubation, the cell cultures were fixed, stained, and then read using an epifluorescent microscope.
- **b.3** 0.2 mL of *M. orale* and *M. pneumoniae* at less than 100 CFU/plate was inoculated onto each of two (2) SP-4 agar plates. 10.0 mL of *M. orale* and *M. pneumoniae* at less than 10 CFU/mL (≤100 CFU/inoculum) were each inoculated into a 75 cm² flask containing 50 mL of sterile SP-4 broth.
- **b.4** The agar plates were placed in an anaerobic GasPak system and incubated at $36 \pm 1^{\circ}$ C for 14 days. The broth cultures were incubated aerobically at $36 \pm 1^{\circ}$ C for a minimum of 14 days and were read each working day for 14 days. On Days 3, 7, and 14, 0.2 mL from each broth culture flask was subcultured onto each of two (2) SP-4 agar plates. These subculture plates were placed in an anaerobic GasPak system and incubated at $36 \pm 1^{\circ}$ C. The subculture plates were observed microscopically for the presence of mycoplasma colonies after a minimum of 14 days incubation.
- c. See Section 15.0, Results, for the results of these controls.

11.0 DATA ANALYSIS

The results of this study were based on visual observations, therefore, no data analysis was required.

12.0 STATISTICAL METHODS

The results of this study were qualitative, therefore, no statistical analysis was required.



13.0 EVALUATION CRITERIA

Final evaluation of the validity of the assay and test article results was based upon the criteria listed below and scientific judgment.

13.1 Indirect Assay

DETECTION OF MYCOPLASMA CONTAMINATION BY INDIRECT ASSAY

Controls	MYCOPLASMA FLUORESCENCE OBSERVED (AT LEAST ONE COVERSLIP REQUIRED FOR THE EVALUATION)
Negative Control	-
M. hyorhinis	+
<i>M. orale</i> (≤100 CFU)	+/-*
M. orale (100 ID ₅₀)	+

*Mycoplasma must be observed for at least one dilution of the poorly cyto-adsorbing mycoplasma species M. orale.

13.2 Direct Assay

DETECTION OF MYCOPLASMA CONTAMINATION BY DIRECT ASSAY

	NEGATIVE CONTROL	M. PNEUMONIAE	M. ORALE
Broth (Color change or turbidity change)	-	+/-	+/-
Agar Day 0 (at least one plate)	-	+	+
Agar Day 3, 7, 14 (at least one plate on one day)	-	+	+
Results	-	+	+

14.0 TEST EVALUATION

14.1 Indirect Assay

Hoechst stain will bind to most DNA containing organisms and organelles present in the culture; this includes indicator cell nuclei, prokaryotes including mycoplasma and cell debris. The source of DNA is determined by the staining pattern. The indicator cell nuclei fluoresce brightly and are generally 10-20 μ m in diameter. Mycoplasma fluorescence is less intense, is extra-nuclear and typically appears as small round bodies approximately 0.3 μ m in diameter.

14.2 Direct Assay

Change in color or turbidity of broth culture can be an indicator of the presence of mycoplasma growth. Fermentative mycoplasma produce acid from the carbohydrates in the medium causing the pH of the medium to drop and the broth to turn yellow in color. Nonfermentative mycoplasma produce ammonia by arginine hydrolysis causing the pH to rise and the broth to turn red. In general, growth of mycoplasma can cause the broth to become turbid. These changes must be confirmed by agar plate subculture or DNA-staining since changes in the appearance of the broth culture can also be caused by the properties of the inoculum.

Mycoplasma colonies grow down into the agar causing the center of the colony to appear opaque and the peripheral surface growth to appear translucent. These "fried-egg" colonies vary in size, 10-500 μ m, and can be readily observed unstained using a light microscope.



Copy of Original

14.3 Indirect Assay and Direct Assay Results Interpretation

JF:		Ţ	EST ARTIC	LE	
Mycoplasmal fluorescence	-	+	+/-	+/-	-
Broth (Color change or turbidity change)	-	+/-	+/-	+/	+*
Agar - Day 0 (at least one plate)	-	+/-	+/-	+	-
Agar - Day 3, 7, 14 (at least one plate on one day)	-	+/-	+	+/-	-
THEN: OVERALL FINAL RESULT	-	+	+	+	-

*A change in the appearance of a broth culture must be confirmed by positive subculture plate(s).

14.4 Positive Results

The test article is considered positive if the direct assay (agar or broth media procedure) or the indirect assay (indicator cell culture procedure) show evidence of mycoplasma contamination and resemble the positive controls for the procedure.

14.5 Negative Results

The test article is considered as negative if both the direct assay (agar and broth media procedure) and the indirect assay (indicator cell culture procedure) show no evidence of mycoplasma contamination and resemble the negative control for each procedure.

15.0 RESULTS

Indirect Assay and Direct Assay Results

		DIR		
	INDIRECT	BROTH FLASKS	Agar Plates	OVERALL
Test Article: WA09-DL-5	Negative	Negative	Negative	Negative
Negative Control	Negative	Negative	Negative	Negative
M. hyorhinis	Positive			Positive
M. orale	Positive	Positive	Positive	Positive
M. pneumoniae		Positive	Positive	Positive

For the indirect assay, the coverslips for the undiluted test article were read and determined negative.

16.0 ANALYSIS AND CONCLUSION

- **16.1** The results of the negative and positive controls indicated the validity of this test.
- **16.2** These findings indicated that the test article, WA09-DL-5, is considered negative for the presence of mycoplasma contamination.



17.0 DEVIATIONS: None.

18.0 AMENDMENTS: The study directorship was reassigned to Sheri Zielinski.

19.0 RECORD RETENTION

An exact copy of the original final report and all raw data pertinent to this study will be stored at WuXi AppTec, Inc., 2540 Executive Drive, St. Paul, MN 55120. It is the responsibility of the Sponsor to retain a sample of the test article.

20.0 TECHNICAL REFERENCES

- **20.1** Barile, Michael F. and McGarrity, Gerard J. (1983). "Isolation of Mycoplasmas from Cell Culture by Agar and Broth Techniques." Methods in Mycoplasmology, Vol II, ed. J.G. Tully and S. Razin. (New York: Academic Press) pp. 159-165.
- **20.2** Del Giudice, Richard A. and Joseph G. Tully. 1996. "Isolation of Mycoplasma from Cell Cultures by Axenic Cultivation Techniques," ed. J.G. Tully and S. Razin, Molecular and Diagnostic Procedures in Mycoplasmology, Vol. II (New York: Academic Press).
- **20.3** McGarrity, Gerard J. and Barile, Michael F. 1983. "Use of Indicator Cell Lines for Recovery and Identification of Cell Culture Mycoplasmas," ed. J.G. Tully and S. Razin, Methods in Mycoplasmology, Vol. II (New York: Academic Press).
- **20.4** Masover, Gerald and Frances Becker. 1996. "Detection of Mycoplasma by DNA Staining and Fluorescent Antibody Methodology," ed. J.G. Tully and S. Razin, Molecular and Diagnostic Procedures in Mycoplasmology, Vol. II (New York: Academic Press).
- **20.5** Schmidt, Nathalie J. and Emmons, Richard W. 1989. "Cell Culture Procedures for Diagnostic Virology," ed. Nathalie J. Schmidt and Richard W. Emmons, 6th ed., Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections (Washington: American Public Health Association).
- **20.6** U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER). 1993. "Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals."

(For Laboratory Use Only)
WuXi AppTec Study #
Accession #//ł

1



PROTOCOL TITLE:	MYCOPLASMA DETECTION: "POINTS TO CONSIDER"
TEST CODE:	30055
PERFORMING LABORATORY:	WuXi AppTec, Inc. 2540 Executive Drive St. Paul, MN 55120
EFFECTIVE DATE:	3 June 2008

GLP PROTOCOL:

30055F

Technical Management

Quality Assurance has reviewed this protocol for compliance with applicable regulatory requirements and internal procedures.

PROPRIETARY INFORMATION

This document is provided with the understanding that the recipient shall recognize it contains WuXi AppTec proprietary information, that it shall be kept confidential by the person and/or company to whom it is addressed, and that it shall be used for no other purpose than assessing and approving the described services to be performed by WuXi AppTec or for the purpose of regulatory submission.

Page 1 of 9



MYCOPLASMA DETECTION: "POINTS TO CONSIDER"

1.0 PURPOSE

This test is designed to demonstrate that a test article consisting of a cell bank, production or seed lots, or raw materials is free of mycoplasmal contamination, according to "Points to Consider" criteria.

2.0 TEST FACILITY: WuXi AppTec, Inc. 2540 Executive Drive St. Paul, MN 55120

3.0 SCHEDULING / DISCLAIMER

- **3.1** Test protocol initiation is generally within 10 working days after receipt of the test article, a signed Client Protocol Approval form, and a signed sample submission form. The Client Protocol Approval form and the sample submission form serve as addenda to this protocol. Written notification of the proposed initiation and completion dates will be provided at the time the test article and signed protocol are received by the laboratory. The estimated testing time is 28 days. Verbal results will be available from the Study Director upon completion of the study with the written quality assurance audited report to follow approximately 10 working days after completion of the study.
- **3.2** If a test, or a portion of it, must be repeated due to failure by WuXi AppTec to adhere to specified procedures, it will be repeated free of charge. If a test must be repeated, or a portion of it, due to failure of internal controls or failure to meet assay validity requirements, it will be repeated free of charge. "Methods Development" fees shall be assessed, however, if the test article and test system require modifications due to complexity and difficulty of testing.
- **3.3** If the Sponsor requests a repeat test, they will be charged for an additional test.
- **3.4** Neither the name of WuXi AppTec nor any of its employees are to be used in advertising or other promotion without written consent from WuXi AppTec.
- **3.5** The Sponsor is responsible for any rejection of the final report by the regulatory agency concerning report format, pagination, etc. To prevent rejection, the Sponsor should carefully review the WuXi AppTec final report and notify WuXi AppTec of any perceived deficiencies in these areas before submission of the report to the regulatory agency. WuXi AppTec will make reasonable changes deemed necessary by the Sponsor, without altering the technical data.

4.0 TEST ARTICLE IDENTIFICATION

Test article information to be included in the final report will be provided solely by the Sponsor on the WuXi AppTec sample submission form attached to this protocol.

Effective Date: 3 June 2008 Page 3 of 9



5.0 TEST ARTICLE CHARACTERIZATION

The Sponsor is responsible for all test and control article characterization data as specified in the GLP regulations. The identity, strength, stability, purity, and chemical composition of the test article are solely the responsibility of the Sponsor. The Sponsor is responsible for supplying to the testing laboratory results of these determinations and any others that may directly impact the testing performed by the testing laboratory, prior to initiation of testing. Furthermore, it is the responsibility of the Sponsor to ensure that the test article submitted for testing is representative of the final product that will be subjected to materials characterization. Any special requirements for handling or storage must be arranged in advance of receipt and the test article must be received in good condition.

The test article will be maintained according to the Sponsor's instructions. The Vero cells are maintained by WuXi AppTec's Cell Production Laboratory.

6.0 EXPERIMENTAL DESIGN

6.1 Overview

Whereas no single test is capable of detecting all mycoplasmal strains, freedom from mycoplasmal contamination may be demonstrated by the use of both an indirect and a direct procedure.

The indirect method (indicator cell culture) of detection allows visualization of mycoplasma, particularly non-cultivable strains, by growing the mycoplasma on an indicator cell line and then staining using a DNA-binding fluorochrome stain (Hoechst stain). The indicator cell line should be easy to grow, have a large cytoplasmic to nuclear area ratio and support the growth of a broad spectrum of mycoplasma species. The African green monkey kidney cell line, Vero, fits this description and is frequently used.

The indirect assay is performed with negative and positive controls. Both a strongly cyto-adsorbing (*M. hyorhinis*) and a poorly cyto-adsorbing (*M. orale*) mycoplasma species are used as positive controls. Poorly cyto-adsorbing mycoplasma species may not give reliable positive results when inoculated in low numbers. A second dilution of *M. orale* may be used to ensure cyto-adsorption. Staining the cultures with DNA-binding fluorochrome allows for the detection of mycoplasma based on the staining pattern observed. Only the cell nuclei demonstrate fluorescence in the negative cultures but nuclear and extra-nuclear fluorescence is observed in positive cultures.

Direct cultivation is a sensitive and specific method for the detection of mycoplasma. The agar and broth media employed supply nutrients necessary for the growth of cultivable mycoplasmas. These media also supply a source of carbon and energy, and favorable growth conditions. The direct assay is performed using negative and positive controls. A fermentative (*M. pneumoniae*) as well as a non-fermentative (*M. orale*) mycoplasma species are used as positive controls.

The procedures employed in this study are based on the methods described in the 1993 Attachment # 2 to the "Points To Consider" document.



6.2 Justification For Selection Of The Test System

Contamination of cell cultures by mycoplasma is a common occurrence and is capable of altering normal cell structure and function. Among other things, mycoplasma may affect cell antigenicity, interfere with virus replication, and mimic viral actions. Testing for the presence of mycoplasma for cell lines used to produce biologicals is recommended by the FDA, Center for Biologics Evaluation and Research (CBER) under Points to Consider.

7.0 PROCEDURE FOR IDENTIFICATION OF THE TEST SYSTEM

7.1 Controls And Reference Materials

- **7.1.1** Sterile SP-4 glucose broth will serve as the negative control inoculum for the direct and indirect assays.
- **7.1.2** Optional: Cell culture medium may be added as an additional negative control for the indirect assay.

7.1.3 Positive Controls

a. Indirect Assay

- **a.1** Strongly cyto-adsorbing species *M. hyorhinis* GDL (ATCC # 23839) at 100 or fewer colony forming units (CFU) per inoculum.
- **a.2** Poorly cyto-adsorbing species *M. orale* (ATCC #23714) at 100 or fewer CFU per inoculum and at approximately 100 ID_{50.}

b. Direct Assay

- **b.1** Nonfermentative mycoplasma species *M. orale* (ATCC#23714) at 100 or fewer CFU per inoculum.
- **b.2** Fermentative mycoplasma species *M. pneumoniae* FH (ATCC #15531) at 100 or fewer CFU per inoculum.
- 7.2 Testing is performed in strict adherence to WuXi AppTec Standard Operating Procedures (SOPs) which have been constructed to cover all aspects of the work including, but not limited to, receipt, identification, log-in, and tracking of test article(s). Additionally, each test is assigned a unique Project Number. This number is used for identification during the course of the test.

8.0 TEST METHOD

8.1 Indirect (DNA-staining) Assay

8.1.1 Inoculate no less than 1 mL of the negative control and test article directly onto coverslips containing previously incubated Vero cells. Two (2) or more coverslips will be used for each control and test article. Additional dilutions of the test article may be made to eliminate interference of cellular debris with mycoplasma detection.



- **8.1.2** For media samples (EMEM, DMEM, FBS, etc.) that are free of cellular material, inoculate 1 mL of undiluted test article onto four (4) coverslips containing previously incubated Vero cells. Three (3) coverslips will be observed and the fourth will serve as a backup.
- **8.1.3** For trypsin samples, add an equal volume of previously tested and released fetal bovine serum (FBS) to inactivate the trypsin. 1 mL of the inactivated test article will be inoculated onto four (4) coverslips containing previously incubated Vero cells. Three (3) coverslips will be observed and the fourth will serve as a backup.
- **8.1.4** The positive controls, *M. hyorhinis* and *M. orale*, are inoculated in the same manner, using 100 or fewer CFU per inoculum for *M. hyorhinis* and 100 or fewer CFU and at approximately 100 ID₅₀ for *M. orale*.
- **8.1.5** Following reincubation for 3 to 5 days, cells are fixed and then stained with a DNA-binding fluorochrome (Hoechst 33258 stain), and are evaluated for the presence of mycoplasma using epifluorescent microscopy.

8.2 Direct (Microbiological) Assay

- **8.2.1** At least two (2) SP-4 glucose agar plates are inoculated with no less than 0.2 mL per plate of the negative control (sterile SP-4 glucose broth).
- **8.2.2** 50 mL of sterile SP-4 glucose broth is inoculated with no less than 10 mL of the negative control.
- **8.2.3** All test articles are tested neat for the Direct Assay unless dilution is requested by the Sponsor. Sterile phosphate buffered saline (PBS) should be used to prepare dilutions unless an alternate diluent is requested by the Sponsor. The diluent that is used should be free from antibiotics or other materials that are known to interfere with the detection of mycoplasma.
- **8.2.4** The test article is inoculated onto two (2) or more SP-4 glucose agar plates (0.2 mL per plate) and into one (1) broth flask (no less than 10 mL into 50 mL of sterile SP-4 glucose broth).
- 8.2.5 The positive controls, *M. pneumoniae* and *M. orale,* are inoculated in the same manner, using 100 or fewer CFU per inoculum onto each of two (2) or more plates and 10 mL (100 or less CFU per inoculum) into 50 mL of sterile SP-4 glucose broth.
- 8.2.6 Agar plates are incubated anaerobically in a GasPak system at $36 \pm 1^{\circ}$ C for at least 14 days
- 8.2.7 Broth culture flasks are incubated aerobically at $36 \pm 1^{\circ}$ C. Broth cultures are observed daily (normal working days only) for changes in color or turbidity.
- **8.2.8** The broth culture flasks are subcultured on Days 3, 7, and 14 onto SP-4 agar plates. Two (2) or more plates (0.2 mL broth / plate) are inoculated and incubated anaerobically in a GasPak system for at least 14 days.



8.2.9 The agar plates are examined microscopically for the presence of mycoplasma colonies after 14 or more days of incubation.

9.0 METHOD FOR CONTROL OF BIAS: Not applicable.

10.0 DATA ANALYSIS

The results of this study are based on visual observations; therefore no data analysis is required.

11.0 STATISTICAL METHODS

The results of this study are qualitative; therefore no statistical analysis is required.

12.0 ASSAY VALIDITY

Final evaluation of the validity of the assay and test article results will be based upon the criteria listed below and scientific judgment.

12.1 Indirect Assay

DETECTION OF MYCOPLASMA CONTAMINATION BY INDIRECT ASSAY

CONTROLS	MYCOPLASMA FLUORESCENCE OBSERVED (AT LEAST ONE COVERSLIP REQUIRED FOR THE EVALUATION)
Negative Control	
M. hyorhinis	+
<i>M. orale</i> (≤100 CFU)	+/-*
M. orale (100 ID ₅₀)	+

*Mycoplasma must be observed for at least one dilution of the poorly cytoadsorbing mycoplasma species *M. orale.*

- **12.1.1** The negative controls do not exhibit fluorescence typical of mycoplasma contamination.
- **12.1.2** The positive control mycoplasma, *M. hyorhinis*, at \leq 100 CFU per inoculum is detected in at least one (1) coverslip.
- **12.1.3** The positive control mycoplasma, *M. orale*, is detected in at least one (1) coverslip at one (1) concentration (either ≤ 100 CFU per inoculum or 100 ID_{50}).

12.2 Direct Assay

DETECTION OF MYCOPLASMA CONTAMINATION BY DIRECT ASSAY

	NEGATIVE	М.	М,
	CONTROL	PNEUMONIAE	ORALE
Broth (Color change or turbidity change)	-	+/-	+/-
Agar Day 0 (at least one plate)	-	+	+
Agar Day 3, 7, 14 (at least one plate on one day)	-	+	+
Results	-	+	+

12.2.1 The negative controls are negative for mycoplasma throughout the observation period.



- **12.2.2** The positive control mycoplasmas, *M. pneumoniae* and *M orale*, are positive on at least one (1) Day 0 agar plate.
- **12.2.3** The positive control mycoplasmas, *M. pneumoniae* and *M orale*, are positive on at least one (1) sub-culture plate.

13.0 TEST EVALUATION

13.1 Indirect Assay

Hoechst stain will bind to most DNA containing organisms and organelles present in the culture; this includes indicator cell nuclei, prokaryotes including mycoplasma and cell debris. The source of DNA is determined by the staining pattern. The indicator cell nuclei fluoresce brightly and are generally 10 to 20 μ m in diameter. Mycoplasma fluorescence is less intense, extra-nuclear, and typically appears as small round bodies approximately 0.3 μ m in diameter.

13.2 Direct Assay

Change in color or turbidity of broth culture can be an indicator of the presence of mycoplasma growth. Fermentative mycoplasma produce acid from the carbohydrates in the medium causing the pH of the medium to drop and the broth to turn yellow in color. Nonfermentative mycoplasma produce ammonia by arginine hydrolysis causing the pH to rise and the broth to turn red. In general, growth of mycoplasma can cause the broth to become turbid. These changes must be confirmed by agar plate subculture or DNA-staining since broth changes can also be caused by the properties of the inoculum.

Mycoplasma colonies grow down into the agar causing the center of the colony to appear opaque and the peripheral surface growth to appear translucent. These "fried-egg" colonies vary in size, 10-500 μ m, and can be readily observed unstained using a light microscope.

13.3 Indirect Assay and Direct Assay Results Interpretation

IF:		Тє	ST ARTI	CLE	
Mycoplasmal fluorescence	-	+	+/-	+/-	-
Broth (Color change or turbidity change)	-	+/-	+/-	+/-	+*
Agar - Day 0 (at least one plate)	-	+/-	+/-	+	-
Agar - Day 3, 7, 14 (at least one plate on one day)	-	+/-	+	+/-	1
THEN: OVERALL FINAL RESULT	-	+	+	+	-

*A change in the appearance of the broth culture must be confirmed by positive subculture plate(s).

13.3.1 Negative Results

The test article is considered as negative if both the direct assay (agar and broth media procedure) and the indirect assay (indicator cell culture procedure) show no evidence of mycoplasma contamination and resemble the negative control for each procedure.



13.3.2 Positive Results

The test article is considered positive if the direct assay (agar and/or broth media procedure) or the indirect assay (indicator cell culture procedure) show evidence of mycoplasma contamination and resemble the positive controls for each procedure.

13.4 Repeat Assays

A test will be repeated in part or in total if a control failure occurs.

14.0 PROTOCOL CHANGES

If it becomes necessary to make changes in the approved protocol, the revisions and reasons for changes will be documented, signed by the Study Director, dated, maintained with the protocol and reported to the Sponsor. If an event occurs which may have an effect on the validity of the study, the Sponsor will be notified as soon as is practical. If the Study Director is unable to complete the study, an alternate Study Director with full responsibility and authority regarding the study will be assigned.

15.0 FINAL REPORT

The final report will include but will not be limited to: the date of the study initiation and completion, the purpose as stated in the approved protocol, changes in the approved protocol, identification of the test system, a description of the methods used and conclusion as it relates to the test.

16.0 RECORD RETENTION

16.1 Study Specific Documents

All of the original raw data developed exclusively for this study shall be retained according to WuXi AppTec, Inc.'s standard operating procedures for archival. These original data include, but are not limited to the following:

- **16.1.1** All handwritten and equipment generated raw data for control(s) and test article(s).
- **16.1.2** Any protocol amendments/deviation notifications.
- **16.1.3** Memoranda, specifications, and other study specific correspondence relating to interpretation and evaluation of data, other than those documents contained in the final study report.
- **16.1.4** Original signed protocol.
- **16.1.5** Certified copy of final study report.
- **16.1.6** Study-specific SOP deviations made during the study.

16.2 Facility Specific Documents

The following records shall also be retained according to WuXi AppTec, Inc.'s standard operating procedures for archival. These documents include, but are not limited to, the following:

- **16.2.1** SOPs which pertain to the study conducted.
- **16.2.2** Non study-specific SOP deviations made during the course of this study which may affect the results obtained during this study.
- **16.2.3** Methods which were used or referenced in the study conducted.



- **16.2.4** QA reports for each QA inspection with comments.
- **16.2.5** Facility Records: Temperature Logs (ambient, incubator, etc.), Instrument Logs, Calibration and Maintenance Records.
- **16.2.6** Current job descriptions and summary of experience and training for all personnel involved in the study.

17.0 REFERENCES

- **17.1** Barile, Michael F. and McGarrity, Gerard J. (1983). "Isolation of Mycoplasmas from Cell Culture by Agar and Broth Techniques." Methods in Mycoplasmology, Vol II, ed. J.G. Tully and S. Razin. (New York: Academic Press) pp. 159-165.
- **17.2** Del Giudice, Richard A. and Tully, Joseph G. 1996. "Isolation of Mycoplasma from Cell Cultures by Axenic Cultivation Techniques," ed. J.G. Tully and S. Razin, Molecular and Diagnostic Procedures in Mycoplasmology, Vol. II (New York: Academic Press).
- **17.3** McGarrity, Gerard J. and Barile, Michael F. 1983. "Use of Indicator Cell Lines for Recovery and Identification of Cell Culture Mycoplasmas," ed. J.G. Tully and S. Razin, Methods in Mycoplasmology, Vol. II (New York: Academic Press).
- **17.4** Masover, Gerald and Frances Becker. 1996. "Detection of Mycoplasma by DNA Staining and Fluorescent Antibody Methodology," ed. J.G. Tully and S. Razin, Molecular and Diagnostic Procedures in Mycoplasmology, Vol. II (New York: Academic Press).
- **17.5** Schmidt, Nathalie J. and Emmons, Richard W. 1989. "Cell Culture Procedures for Diagnostic Virology," ed. Nathalie J. Schmidt and Richard W. Emmons, 6th ed., Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections (Washington: American Public Health Association).
- **17.6** U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER). 1993. "Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals."

18.0 COMPLIANCE

GLP STATUS: This study will be performed in accordance with FDA, 21 CFR, Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies. The study will be inspected during at least one phase and the final report will be audited by the WuXi AppTec Quality Assurance Unit.

19.0 TEST ARTICLE DISPOSITION

It is the responsibility of the Sponsor to retain a sample of the test material. All unused test material will be discarded following study completion unless otherwise requested by Sponsor.

CLIENT PROTOCOL APPROVAL FORM



PLEASE NOTE THAT TESTING CANNOT BE INITIATED UNTIL THIS FORM IS COMPLETED WITH AN AUTHORIZED SIGNATURE AND THE ORIGINAL IS RETURNED TO WUXI APPTEC.

SPONSOR:





Primary Approval Statement

I have read WuXi AppTec, Inc.'s client protocol, 30055F - Mycoplasma Detection: "Points to Consider". I accept the test method described. I understand that my approval will be valid until one or both of the following occur:

- 1. The protocol is revised and a new version letter is issued.
- 2. The Primary Approver's position with the Sponsor company is terminated or changes, whichever may occur first.

	TITLE: QA Manager
U v	Associate(s) Approval Statement

The Primary Approver (above) has authorized the following Associate(s) to accept the responsibility for submitting samples for testing under this protocol. Each associate understands that their authorization for submission will be valid until one or more of the following has occurred:

- 1. The protocol has been revised and new version letter has been issued.
- The primary Approver's position with the Sponsor company is terminated or changes, whichever may occur first.
- Any of the Associate's positions with the Sponsor company are terminated or change, whichever may occur first.
- The Primary Approver has removed any Associate's authorization by sending a signed and dated letter to WuXi AppTec, ATTN: Client Services.
- I do not wish to have an Associate(s) authorized to initiate testing of samples under this protocol.
- I do wish to have the following Associate(s) authorized to initiate testing of samples under this protocol.

Name of Associate (please print)	Name of Associate (please print)
Name of Associate (please print)	Name of Associate (please print)
WUXI APPTEC, INC.:	
NAME: Todd QuiNA	[.
SIGNATURE:	DATE: 7/368

		PHONE		FAY		ΕΜΔΙΙ
Company Name and Address:			Client /	Account Number: 40(00252	
Sample Designation for Final	& INFORMATION	If resubmitting s	ample material, provide o	riginal AppTec sample A ample (General De		<u>/):</u>
WA09-701	-		hE	5 Cell	-	.
Commercial/Marketed Product?	Species of Origin:	Stability (Expiratio	n Date): Biosafety L	evel: Sample Mat	rix or Buffer Comp	oonents (if appli
SAMPLE SHIPMENT & ST			····· · · · · · · · · · · · · · · · ·		(either))
Controlled Storage Temperate	•		igerated (2° to 8°C)	🗹 Frozen (-10		/ Ultracold (< -6 <i>the Study Direct</i>
Liquid Nitrogen (Availab	le only in Philadelphia)	NOTE: For	virology testing, sampl	e storage conditions v	vill be determined by	
_ • •	amples, AppTec als with internal to help prevent to help orevent	NOTE: For Do Not Freeze/Thaw May Freeze/Thaw # of Times:		Upon test comple	tion, samples to b dditional fee applies pany and acct. # for	e: 🔽 Disca
Liquid Nitrogen (Availab NOTE: For small-quantity liquid se has found the use of cryogenic vie thread closures an effective way to leaking that can result in loss of sam	amples, AppTec als with internal to help prevent ple volume and g shipping.	Do Not Freeze/Thaw May Freeze/Thaw # of Times:		Upon test comple	tion, samples to b	e: 🔽 Disca
Liquid Nitrogen (Availab NOTE: For small-quantity liquid sa has found the use of cryogenic via thread closures an effective way t leaking that can result in loss of sam possible sample contamination durin	amples, AppTec als with internal to help prevent ple volume and g shipping.	Do Not Freeze/Thaw May Freeze/Thaw # of Times:	Sample for Reuse	Upon test comple	tion, samples to b dditional fee applies pany and acct. # for ctly impact the tes	e: 💋 Disca) shipping: ting performed
Liquid Nitrogen (Availab NOTE: For small-quantity liquid se has found the use of cryogenic via thread closures an effective way to leaking that can result in loss of sam possible sample contamination durin SAMPLE CHARACTERIZAT Sample characterization informa IS ATTACHED to this sample IF SUBMITTING A CELL LIN	amples, AppTec als with internal to help prevent ple volume and g shipping. TION INFORMATIO tion, such as strength ble submission form.	Do Not Freeze/Thaw May Freeze/Thaw # of Times: N , homogeneity, purity (2 IS UNAVA HIS SECTION	Sample for Reuse y and stability, and c ILABLE.	Upon test comple Returned (<i>A</i> <i>Provide courier con</i> thers that may dire IS CONSIDERED pomitted for expansio	tion, samples to b dditional fee applies pany and acct. # for ctly impact the tes PROPRIETARY I n will be stored in I	e: 💋 Disca) shipping: ting performed NFORMATIO
Liquid Nitrogen (Availab NOTE: For small-quantity liquid se has found the use of cryogenic via thread closures an effective way to leaking that can result in loss of sam possible sample contamination durin SAMPLE CHARACTERIZAT Sample characterization informa IS ATTACHED to this sample IF SUBMITTING A CELL LIN	amples, AppTec als with internal to help prevent ple volume and g shipping. TION INFORMATIO tion, such as strength ple submission form. NE, COMPLETE TH Ch	Do Not Freeze/Thaw May Freeze/Thaw # of Times: N homogeneity, purity 2 IS UNAVA	Sample for Reuse y and stability, and c ILABLE.	Upon test comple	tion, samples to b dditional fee applies pany and acct. # for ctly impact the tes PROPRIETARY in n will be stored in li x.) o Trypsin / Cells a	e: 🛛 Disca) shipping: ting performec NFORMATIOI
Liquid Nitrogen (Availab NOTE: For small-quantity liquid se has found the use of cryogenic via thread closures an effective way to leaking that can result in loss of sam possible sample contamination durin SAMPLE CHARACTERIZAT Sample characterization informa IS ATTACHED to this samp	amples, AppTec als with internal o help prevent ple volume and g shipping. TION INFORMATIO tion, such as strength ole submission form. NE, COMPLETE TH Ch D Supplements/Conce	Do Not Freeze/Thaw May Freeze/Thaw # of Times: N N N N N N N N N N N N N	Sample for Reuse y and stability, and o ILABLE. NOTE: Cells sub Subculturing: (Cl Requires Tryp Requires Tryp Requires Tryp	Upon test comple	tion, samples to b dditional fee applies pany and acct. # for ctly impact the tes PROPRIETARY in n will be stored in li x.) o Trypsin / Cells a	e: 2 Disca) shipping: ting performed INFORMATION

See Page 2 of this form to provide additional information and sample submission authorization. * Stored at 2-60°C at WaXi AppTec St. Paul, 57/368 SSF10013-2D

FOR AL	PPIEC USE				
CLIENT	DATE	ACCESSION #	Con	1 of Oric	inal
			P J	i wi wing	JEENNE

REQUESTED TESTING If more space is need	led to list requested as	says, attach a s	econd copy of this s	heet.	
BRIEF NAME / DESCRIPTION OF ASSAY	PROTOCOL NUMBER	indicate if	AMOUNT C ALLOCATED F	Check if requesting STAT [Additional	
		R&D	# of Tubes	Vol. In Tube	fees apply]
Mycoplasma	30055		l	15ml	
·					
	· · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·	
	· · · · ·				
	·				
	· · · · · · · · · · · · · · · · · · ·				

	PROV	DE THE FOLLOWING INFORMATION, AS APPLICABLE			
If ordering Protocol # 37000, list cell lines:		Check one: 🛛 F	Plates 🛛 Flasks		
		Check one: 🗖 1	4-day 🛛 28-day		
Concentration per For Patient or Test Dose Units:					
Check One: DParticles	🗆 PFU	For DNA Detection Assays Amount of material to test:	· · · · · · · · · · · · · · · · · · ·		
FOR STERILITY TESTING:		sample been submitted before? □Yes □No iducted on this sample? □Yes □No Does sample contain antib	iotics? □Yes □No		
COMMENTS / SAMPLE P	REPARATION &	SPECIAL INSTRUCTIONS (Including pre-testing information such as diluti	ions, reconstitution, etc.)		

IMPORTANT INSTRUCTIONS REGARDING THIS FORM. READ CAREFULLY BEFORE SIGNING AUTHORIZATION BELOW.

This sample submission form-which must accompany each submitted sample -acts as the official record for what is being requested/required of AppTec regarding this particular sample. It is essential that clients provide <u>complete</u> information on this form for ALL areas (as applicable to the sample). If the required information cannot be provided within the spaces on this form, client should <u>attach</u> any additional information that may be critical regarding sample description, handling, preparation, etc. (even if this information may have been provided previously to AppTec). Failure to provide this information could result in testing delays or other issues. AppTec will not be held responsible for information not provided by client. In addition, if re-testing is required because of missing or incomplete information, charges for both the initial testing and retesting will be the client's responsibility.

SAMPLE SUBMISSION AUTHORIZATION

For testing to be initiated, this section must be signed by the same sponsor representative who approved the protocol(s) listed above.

AppTec – Philadelphia • 4751 League Island Blvd. • Philadelphia, PA 19112 • 800.622.8820 • 215.218.5500 • *FAX* 215.218.5990 AppTec – Atlanta • 1265 Kennestone Circle • Marietta, GA 30066 • 888.847.6633 • 770.514.0262 • *FAX* 770.514.0294 AppTec – St. Paul • 2540 Executive Drive • St. Paul, MN 55120 • 888.794.0077 • 651.675.2000 • *FAX* 651.675.2005

GLP COMPLIANT TEST PROTOCOL AMENDMENT

- 1.0 Amendment Number:
- 2.0 Effective Date: August 11, 2008
- 3.0 Amendment Date: August 11, 2008
- 4.0 Sponsor: WiCell Research Institute



1

- 5.0 Test Facility: WuXi AppTec Inc. 2540 Executive Drive St. Paul, MN 55120
- 6.0 WuXi AppTec Protocol Number: 30055F
- 7.0 WuXi AppTec Project Number: 108515
- 8.0 Modification to Protocol: The Study Directorship of this assay was reassigned to Sheri Zielinski.
- 9.0 Reason for Change: Study director change
- 10.0 Impact to Protocol Interpretation: none
- **11.0 Review** Signatures below represent authorization of the amendment (e.g. authorize change to the SOP and protocol).

relinster Study Director

NA Sponsor (if applicable) <u>8/13/08</u> Date

Copy of Original

NA Date

Check applicable box as task is completed:

NA

- Annotation made in protocol
- Special Instructions Worksheet/Study Worksheets Updated
- IACUC Protocol Amended/Updated

The following should be completed for amendments that alter the study schedule:

- ☑ □ Project Schedules updated
- ☑ Worksheets updated
- Project Folder Annotations/Stamps updated
- □ Critical Phase Audited Re-scheduled
- □ Cage Card Termination Date updated
- I Special Instruction Worksheet updated

Updates Complete: ndunn len


Study Director or Manager



Report Date: June 26, 2013

Case Details:

Cell Line: WA09-DL-5 Passage #: p29 **Date Completed:** 7/8/2008 **Cell Line Gender:** female **Investigator:** National Stem Cell Bank **Specimen:** hESC on MEF feeder **Date of Sample:** 7/2/2008 *Tests, Reason for:* Confirm normal karyotype. **Results:** 46.XX Completed by ST, CLSp(CG), on 7/7/2008 Reviewed and interpreted by KDM, PhD, FACMG, on 7/8/2008 *Interpretation:* No abnormalities were detected at the stated band level of resolution.



Cell: S01-02 Slide: A Slide Type: Karyotyping Cell Results: Karyotype: 46,XX

of Cells Counted: 20
of Cells Karyotyped: 3
of Cells Analyzed: 6
Band Level: 450-550

Results Transmitted by Fax / Email / Post Sent By:_____

Date:____ Sent To:_



WiCell Cytogenetics Report: 000137 NSCB3942

Report Date: December 4, 2009

Case Details:

Cell Line: WA09 DL-5 (Female)

Reference: WA01 p37 (Male)

Investigator: National Stem Cell Bank

Specimen: hES cells on MEFs


Date of Sample: 7/3/2008

Reason for Testing: NSCB Testing

GEO Accession #: GSM325499

aCGH Results:

Results are given in the attached Excel spreadsheet labeled "report." There were 95 copy number gains and losses identified by modified circular binary segmentation¹. The analysis summary is depicted in the ratio plot below with copy number gains shown in green and losses in red. This data was generated using OneClickCGH^m software.



Interpretation: The data shown in the table below are derived from the attached Excel spreadsheet labeled "select". These copy number changes are measures of sensitivity^{2, 3} or may be related to differential gene expression that is monitored in the NSCB characterization protocol and the ISCI study⁴. Changes associated with karyotype abnormalities and/or previously reported publications^{2, 5} are also listed. Copy number changes designated by an * in "select" report indicate inconsistency with the reference standard.

X-chromosome Gains or Losses at Pseudoautosomal Loci ³	2 of 2
Published Copy Number Changes ^{5,6}	2 of 8
Reference DNA Copy Number Changes ²	13 of 17
Select Differentially Expressed Genes	0 of 88

These results are consistent with karyotype results [46,XX] as reported in 000637-070208,3942-KAR.

Page | 1



WiCell Cytogenetics Report: 000137 NSCB3942

Test sample gain or loss is consistent with the opposite gender reference standard. Additional analysis of this data was performed using different ratio settings and different window averaging.

Results Completed By: Reviewed and Interpreted By:

MS, CLSp(CG) . PhD. FACMG

aCGH Specifications:

- Platform: NimbleGen 385K array (HG18 CGH 385K WG Tiling v2)
- Relative copy number is determined by competitive differential hybridization of labeled genomic DNA to the 385,000
 oligonucleotide whole genome tiling array
- Probe length = 50-75mers for v1 and 60mers for v2, spanning non-repetitive regions of the human genome
- Median probe spacing = 6270bp for v1 and 7073bp for v2
- Analysis software: NimbleScan™, SignalMap™, OneClickCGH (RBS v1.0)™, OneClickFusion (RBS v1.0)™
- Array design, genomic position, genes and chromosome banding are based on HG18.
- Analysis is based on examination of unaveraged and/or 60Kbp (10X) averaged data tracks as noted. Settings for data analysis in Infoquant include an average log-ratio threshold of 0.2 and no minimum aberration length.
- Raw data is deposited in GEO, accession number shown above.
- Reported gains and losses are based on test to reference ratios within OneClickCGH™, size of aberration, 8-9 probes per gene, and coverage of at least one reported gene or overlap with the DGV.

Limitations: This assay will detect aneuploidy, deletions, duplications of represented loci, but will not detect balanced alterations (reciprocal translocations, Robertsonian translocations, inversions, and insertions), point mutations, uniparental disomy or imbalances less than 30kb in size. Copy number variants can be attributable to the test or reference samples used. Exact limits of detectable mosaicism have not been determined, but >20% mosaicism is reported to be visualized by aCGH. Actual chromosomal localization of copy number change is not determined by this assay. Other mapping procedures are required for determining chromosomal localization.

Literature Sources:

- ^{1.} Olshen, A., Venkatraman, E., Lucito, R., Wigler, M. (2004). Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics, 5, 4, 557-572.
- ². Internal Data, Unpublished.
- ^{3.} Mumm, S., Molini, B., Terrell, J., Srivastava, A., Schlessinger, D. (1997). Evolutionary Features of the 4-Mb Xq21.3 XY Homology Region Revealed by a Map at 60-kb Resolution. Genome Research, 7, 307-314.
- ^{4.} Adewumi, O., Aflatoonian A., Ahrlund-Richter L., Amit M., Andrews P., Beighton G., et al. (2007). Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nature Biotechnology, 25, 803-816.
- Werbowetski-Ogilvie, T., Bosse, M., Stewart, M., Schnerch, A., Ramos-Mejia, V., Rouleau A., et al. (2008). Characterization of human embryonic stem cells with features of neoplastic progression. Nature Biotechnology, 27, 91-97.
- ⁶ Wu, H., Kim, K., Mehta, K., Paxia, S., Sundstrom, A., Anantharaman, T., et al. (2008). Copy number variant analysis of human embryonic stem cells. Stem Cells, 26, 1484-1489.

Recommendations: For relevant findings, confirmation and localization is recommended. Contact <u>cytogenetics@wicell.org</u> to request further testing.

Results Transmitted	l by Fax /	Email / Post
Sent By:	-	

Date:			
Sent To:			



Procedures performed: SOP-CH-101 SOP-CH-102 SOP-CH-103 SOP-CH-105 Cell: WA09-DL-5 Passage p33 SampleID: 3942-FAC Date of: (*mm/dd/yy*) acquisition: 07/24/08 file creation: 08/01/08 file submission: 08/01/08

